Circulating miR-21 levels were upregulated in old, frail, type-2 diabetes mellitus HFpEF patients, compared to age-matched healthy controls, and was reduced after 3-month treatment with SGLT-2 inhibitor empagliflozin (122). Here, SLC5A2 is linked to type 2 diabetes mellitus.